Skip to content

Svennilson Peter

Follow

13F filer, CIK 1606074, SAN FRANCISCO, CA

Svennilson Peter reported $113,470,000 across 4 holdings for the quarter ended 2018-12-31, in a 13F-HR filed 2019-02-13.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001606074-19-000001

Period
2018-12-31
Reported value
$113M
Holdings
4
Top 10 weight
100%
New
Sold out

Stakes and trades reported after 2018-12-31

13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.

  • SRZN SURROZEN INC: 13D/A 3,813,501 shares, 18.2% of the class, 13D/A filed 2026-11-18, 0001193125-26-467393Timeline
    Accepted , ingested
  • TNYA TENAYA THERAPEUTICS INC: 13D/A 49,313,559 shares, 21.6% of the class, 13D/A filed 2026-11-16, 0001193125-26-463722Timeline
    Accepted , ingested

Holdings, Q4 2018

Share positions as resolved from 13F-HR 0001606074-19-000001, largest first. % of portfolio is the value over $113,470,000, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
GRITSTONE BIO INCGRITSTONE BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2017Q1: restricted; 2017Q2: restricted; 2017Q3: restricted; 2017Q4: restricted; 2018Q1: restricted; 2018Q2: restricted; 2018Q3: restricted; 2018Q4: 3,102,934 shares 3,102,934$47.9M42.25%
RCUSARCUS BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2017Q1: restricted; 2017Q2: restricted; 2017Q3: restricted; 2017Q4: restricted; 2018Q1: restricted; 2018Q2: restricted; 2018Q3: restricted; 2018Q4: 3,540,850 shares 3,540,850$38.1M33.61%Timeline
CONSTELLATION PHARMACEUTICALCONSTELLATION PHARMACEUTICALQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2017Q1: restricted; 2017Q2: restricted; 2017Q3: restricted; 2017Q4: restricted; 2018Q1: restricted; 2018Q2: restricted; 2018Q3: restricted; 2018Q4: 4,677,938 shares 4,677,938$18.8M16.53%
IMMUNE DESIGN CORP.IMMUNE DESIGN CORP.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2017Q1: restricted; 2017Q2: restricted; 2017Q3: restricted; 2017Q4: restricted; 2018Q1: restricted; 2018Q2: restricted; 2018Q3: restricted; 2018Q4: 6,642,942 shares 6,642,942$8.64M7.61%

How Q4 2018 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001606074-19-000001 base2019-02-13acceptance time not in the bulk data set